CR20200542A - Anticuerpos anti-componente de complemento y métodos de uso - Google Patents
Anticuerpos anti-componente de complemento y métodos de usoInfo
- Publication number
- CR20200542A CR20200542A CR20200542A CR20200542A CR20200542A CR 20200542 A CR20200542 A CR 20200542A CR 20200542 A CR20200542 A CR 20200542A CR 20200542 A CR20200542 A CR 20200542A CR 20200542 A CR20200542 A CR 20200542A
- Authority
- CR
- Costa Rica
- Prior art keywords
- antibodies
- methods
- complement component
- complement
- individual
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
<p>La invención proporciona anticuerpos anti-componente de complemento tales como anticuerpos anti-C1s y anticuerpos anti-C1r, y métodos para usar los mismos. La invención también proporciona formulaciones farmacéuticas que comprenden los anticuerpos y métodos para tratar a un individuo que tenga una enfermedad o trastorno mediado por el complemento que comprenden la administración del anticuerpo al individuo. Se evalúan la especificidad de unión y la función de desplazamiento de C1q de los anticuerpos anti-C1s y anticuerpos anti-C1r. La función de neutralización del complemento dependiente del tiempo y la unión a las proteínas C1s o C1r nativas y truncadas también se muestran para los anticuerpos.</p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018077527 | 2018-04-13 | ||
| JP2018188770 | 2018-10-04 | ||
| PCT/JP2019/015919 WO2019198807A1 (en) | 2018-04-13 | 2019-04-12 | Anti-complement component antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200542A true CR20200542A (es) | 2021-01-18 |
Family
ID=68164028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200542A CR20200542A (es) | 2018-04-13 | 2019-04-12 | Anticuerpos anti-componente de complemento y métodos de uso |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210198347A1 (es) |
| EP (1) | EP3774892A4 (es) |
| JP (2) | JP7333789B2 (es) |
| KR (1) | KR20200143459A (es) |
| CN (1) | CN112313249A (es) |
| AU (1) | AU2019250403A1 (es) |
| BR (1) | BR112020018357A2 (es) |
| CA (1) | CA3094312A1 (es) |
| CL (2) | CL2020002610A1 (es) |
| CR (1) | CR20200542A (es) |
| IL (1) | IL277827A (es) |
| MA (1) | MA52248A (es) |
| MX (1) | MX2020010528A (es) |
| PE (1) | PE20201447A1 (es) |
| SG (1) | SG11202010125VA (es) |
| WO (1) | WO2019198807A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3597747B1 (en) | 2012-08-24 | 2023-03-15 | Chugai Seiyaku Kabushiki Kaisha | Mouse fcgammarii-specific fc antibody |
| EP3783017A1 (en) | 2013-04-02 | 2021-02-24 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
| AU2020275348A1 (en) * | 2019-05-15 | 2021-12-09 | Chugai Seiyaku Kabushiki Kaisha | An antigen-binding molecule, a pharmaceutical composition, and a method |
| JP2021063075A (ja) * | 2019-10-16 | 2021-04-22 | 中外製薬株式会社 | 抗体、薬学的組成物、および方法 |
| WO2022031978A1 (en) * | 2020-08-06 | 2022-02-10 | Bioverativ Usa Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| WO2022103871A1 (en) * | 2020-11-10 | 2022-05-19 | Wyomingv Immune, Inc. | Therapeutic compositions for the treatment of covid-19 |
| AR125344A1 (es) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
| EP4337332A2 (en) | 2021-07-13 | 2024-03-20 | Mabwell Therapeutics Inc. | Anti-c1s antibodies and uses thereof |
| CN117327732A (zh) * | 2022-12-31 | 2024-01-02 | 义翘神州(泰州)科技有限公司 | 充分自裂解重组C1s蛋白的表达质粒组合、表达宿主细胞及表达方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI564021B (zh) | 2008-04-11 | 2017-01-01 | Chugai Pharmaceutical Co Ltd | Repeated binding of antigen to antigen binding molecules |
| HUP0900319A2 (en) * | 2009-05-25 | 2011-01-28 | Eotvos Lorand Tudomanyegyetem | New peptides, method of producing therof and use thereof |
| TWI667257B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| IN2015KN00015A (es) * | 2012-06-18 | 2015-07-31 | Omeros Corp | |
| US20160053023A1 (en) * | 2013-04-09 | 2016-02-25 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
| WO2014186599A2 (en) * | 2013-05-15 | 2014-11-20 | Annexon, Inc. | Anti-complement factor c1s antibodies and uses thereof |
| AU2015343029B2 (en) * | 2014-11-05 | 2021-07-29 | Annexon, Inc. | Humanized anti-complement factor C1q antibodies and uses thereof |
| HRP20230093T1 (hr) * | 2015-04-06 | 2023-03-31 | Bioverativ Usa Inc. | Humanizirana anti-c1s protutijela i postupci njihove primjene |
| JP6976943B2 (ja) * | 2015-11-24 | 2021-12-08 | アネクソン，インコーポレーテッド | 抗補体因子Ｃ１ｑ Ｆａｂ断片及びその使用 |
-
2019
- 2019-04-12 BR BR112020018357-1A patent/BR112020018357A2/pt unknown
- 2019-04-12 KR KR1020207032744A patent/KR20200143459A/ko unknown
- 2019-04-12 JP JP2020555924A patent/JP7333789B2/ja active Active
- 2019-04-12 PE PE2020001585A patent/PE20201447A1/es unknown
- 2019-04-12 WO PCT/JP2019/015919 patent/WO2019198807A1/en active Application Filing
- 2019-04-12 EP EP19784866.6A patent/EP3774892A4/en active Pending
- 2019-04-12 CR CR20200542A patent/CR20200542A/es unknown
- 2019-04-12 MX MX2020010528A patent/MX2020010528A/es unknown
- 2019-04-12 CN CN201980038684.5A patent/CN112313249A/zh active Pending
- 2019-04-12 MA MA052248A patent/MA52248A/fr unknown
- 2019-04-12 US US17/046,395 patent/US20210198347A1/en not_active Abandoned
- 2019-04-12 AU AU2019250403A patent/AU2019250403A1/en active Pending
- 2019-04-12 CA CA3094312A patent/CA3094312A1/en active Pending
- 2019-04-12 SG SG11202010125VA patent/SG11202010125VA/en unknown
-
2020
- 2020-10-06 IL IL277827A patent/IL277827A/en unknown
- 2020-10-09 CL CL2020002610A patent/CL2020002610A1/es unknown
-
2023
- 2023-06-16 CL CL2023001793A patent/CL2023001793A1/es unknown
- 2023-08-15 JP JP2023132187A patent/JP2023154049A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3094312A1 (en) | 2019-10-17 |
| JP2023154049A (ja) | 2023-10-18 |
| PE20201447A1 (es) | 2020-12-10 |
| WO2019198807A1 (en) | 2019-10-17 |
| SG11202010125VA (en) | 2020-11-27 |
| MX2020010528A (es) | 2020-11-06 |
| EP3774892A1 (en) | 2021-02-17 |
| CL2023001793A1 (es) | 2023-12-15 |
| AU2019250403A1 (en) | 2020-11-19 |
| KR20200143459A (ko) | 2020-12-23 |
| JP7333789B2 (ja) | 2023-08-25 |
| CL2020002610A1 (es) | 2021-02-12 |
| BR112020018357A2 (pt) | 2020-12-29 |
| EP3774892A4 (en) | 2022-02-16 |
| IL277827A (en) | 2020-11-30 |
| MA52248A (fr) | 2021-02-17 |
| CN112313249A (zh) | 2021-02-02 |
| JP2021521206A (ja) | 2021-08-26 |
| US20210198347A1 (en) | 2021-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200542A (es) | Anticuerpos anti-componente de complemento y métodos de uso | |
| MX2019012223A (es) | Anticuerpos anti-cd137 y metodos de uso de los mismos. | |
| PH12017502358A1 (en) | Factor xi antibodies and methods of use | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| MX2018015285A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| PH12019501387A1 (en) | Anti-cd3 antibody and molecules comprising the antibody | |
| MX2018015277A (es) | Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco. | |
| MX2021001902A (es) | Anticuerpos que se unen a histona 2a y/o 4 citrulinada. | |
| EA202192146A1 (ru) | Антитела к клаудину 6 и их применение | |
| MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
| MX2020009296A (es) | Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso. | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
| EA201990895A1 (ru) | Антитела к о1 и варианты их применения | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| WO2018027124A8 (en) | ANTI-O2 ANTIBODIES AND USES THEREOF | |
| EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
| MX2021000387A (es) | Fragmentos de union a fc que comprenden un sitio de union al antigeno cd137. | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
| MX2020001287A (es) | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. | |
| EA202190382A1 (ru) | Фармацевтические составы на основе маскированных антител | |
| EA202092593A1 (ru) | Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение | |
| MX2021007677A (es) | Proteinas de union multiespecificas basadas en pseudofab. | |
| EA202090671A1 (ru) | Ограниченные условно активируемые связывающие белки |